PubRank

Ernesto Freire

Author PubWeight™ 90.71‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites. Nature 2002 9.62
2 Small-molecule CD4 mimics interact with a highly conserved pocket on HIV-1 gp120. Structure 2008 2.74
3 Small-molecule inhibitors of HIV-1 entry block receptor-induced conformational changes in the viral envelope glycoproteins. Proc Natl Acad Sci U S A 2004 2.44
4 Identification of the functional core of the influenza A virus A/M2 proton-selective ion channel. Proc Natl Acad Sci U S A 2009 2.32
5 Thermodynamics of binding of a low-molecular-weight CD4 mimetic to HIV-1 gp120. Biochemistry 2006 1.99
6 The linkage between protein folding and functional cooperativity: two sides of the same coin? Annu Rev Biophys Biomol Struct 2001 1.90
7 Adding calorimetric data to decision making in lead discovery: a hot tip. Nat Rev Drug Discov 2009 1.74
8 A major role for a set of non-active site mutations in the development of HIV-1 protease drug resistance. Biochemistry 2003 1.74
9 Epsin N-terminal homology domains perform an essential function regulating Cdc42 through binding Cdc42 GTPase-activating proteins. Proc Natl Acad Sci U S A 2006 1.50
10 ITC in the post-genomic era...? Priceless. Biophys Chem 2004 1.50
11 Adaptive inhibitors of the HIV-1 protease. Prog Biophys Mol Biol 2005 1.47
12 Multidrug resistance to HIV-1 protease inhibition requires cooperative coupling between distal mutations. Biochemistry 2003 1.44
13 Characterization of protein-protein interactions by isothermal titration calorimetry. Methods Mol Biol 2004 1.43
14 Isothermal titration calorimetry to determine association constants for high-affinity ligands. Nat Protoc 2006 1.43
15 Soluble mimetics of human immunodeficiency virus type 1 viral spikes produced by replacement of the native trimerization domain with a heterologous trimerization motif: characterization and ligand binding analysis. J Virol 2005 1.42
16 Compensating enthalpic and entropic changes hinder binding affinity optimization. Chem Biol Drug Des 2007 1.38
17 Inhibition of HIV-2 protease by HIV-1 protease inhibitors in clinical use. Chem Biol Drug Des 2008 1.38
18 Overcoming drug resistance in HIV-1 chemotherapy: the binding thermodynamics of Amprenavir and TMC-126 to wild-type and drug-resistant mutants of the HIV-1 protease. Protein Sci 2002 1.33
19 Overcoming roadblocks in lead optimization: a thermodynamic perspective. Chem Biol Drug Des 2006 1.31
20 Structure-based design, synthesis, and characterization of dual hotspot small-molecule HIV-1 entry inhibitors. J Med Chem 2012 1.29
21 Amplification of the effects of drug resistance mutations by background polymorphisms in HIV-1 protease from African subtypes. Biochemistry 2002 1.27
22 Transitions to and from the CD4-bound conformation are modulated by a single-residue change in the human immunodeficiency virus type 1 gp120 inner domain. J Virol 2009 1.23
23 Identification of novel inhibitors of the SARS coronavirus main protease 3CLpro. Biochemistry 2004 1.20
24 Binding thermodynamics of statins to HMG-CoA reductase. Biochemistry 2005 1.20
25 Mode of action for linear peptide inhibitors of HIV-1 gp120 interactions. Biochemistry 2004 1.16
26 Interactions of HIV-1 proteins gp120 and Nef with cellular partners define a novel allosteric paradigm. Curr Protein Pept Sci 2004 1.12
27 Structural parameterization of the binding enthalpy of small ligands. Proteins 2002 1.10
28 Isothermal titration calorimetry. Curr Protoc Cell Biol 2004 1.10
29 Structural determinants for affinity enhancement of a dual antagonist peptide entry inhibitor of human immunodeficiency virus type-1. J Med Chem 2008 1.07
30 Design, synthesis and biological evaluation of small molecule inhibitors of CD4-gp120 binding based on virtual screening. Bioorg Med Chem 2010 1.06
31 Structure-Based Design and Synthesis of an HIV-1 Entry Inhibitor Exploiting X-Ray and Thermodynamic Characterization. ACS Med Chem Lett 2013 1.05
32 The active core in a triazole peptide dual-site antagonist of HIV-1 gp120. ChemMedChem 2010 1.05
33 Structure-based design, synthesis and validation of CD4-mimetic small molecule inhibitors of HIV-1 entry: conversion of a viral entry agonist to an antagonist. Acc Chem Res 2014 1.04
34 A structural and thermodynamic escape mechanism from a drug resistant mutation of the HIV-1 protease. Proteins 2004 1.02
35 Finding a better path to drug selectivity. Drug Discov Today 2011 0.99
36 The binding of HIV-1 protease inhibitors to human serum proteins. Biophys Chem 2003 0.99
37 Long-range cooperative interactions modulate dimerization in SARS 3CLpro. Biochemistry 2006 0.98
38 Beta-turn Phe in HIV-1 Env binding site of CD4 and CD4 mimetic miniprotein enhances Env binding affinity but is not required for activation of co-receptor/17b site. Biochemistry 2002 0.98
39 Inhibiting early-stage events in HIV-1 replication by small-molecule targeting of the HIV-1 capsid. J Virol 2012 0.98
40 How much binding affinity can be gained by filling a cavity? Chem Biol Drug Des 2009 0.97
41 Protease inhibition in African subtypes of HIV-1. AIDS Rev 2003 0.97
42 High-affinity inhibition of a family of Plasmodium falciparum proteases by a designed adaptive inhibitor. Biochemistry 2003 0.97
43 Some binding-related drug properties are dependent on thermodynamic signature. Chem Biol Drug Des 2011 0.96
44 Thermodynamics-based drug design: strategies for inhibiting protein-protein interactions. Future Med Chem 2011 0.96
45 Thermodynamic rules for the design of high affinity HIV-1 protease inhibitors with adaptability to mutations and high selectivity towards unwanted targets. Int J Biochem Cell Biol 2004 0.95
46 Binding thermodynamics of the N-terminal peptide of the CCR5 coreceptor to HIV-1 envelope glycoprotein gp120. Biochemistry 2009 0.95
47 Naturally occurring variability in the envelope glycoprotein of HIV-1 and development of cell entry inhibitors. Biochemistry 2010 0.94
48 Design of inhibitors against HIV, HTLV-I, and Plasmodium falciparum aspartic proteases. Biol Chem 2004 0.93
49 Optimization of CD4/gp120 inhibitors by thermodynamic-guided alanine-scanning mutagenesis. Chem Biol Drug Des 2013 0.92
50 Nudel/NudE and Lis1 promote dynein and dynactin interaction in the context of spindle morphogenesis. Mol Biol Cell 2013 0.89
51 Development of broad-spectrum halomethyl ketone inhibitors against coronavirus main protease 3CL(pro). Chem Biol Drug Des 2008 0.88
52 Structural and thermodynamic basis of resistance to HIV-1 protease inhibition: implications for inhibitor design. Curr Drug Targets Infect Disord 2003 0.88
53 Photochemical control of RNA structure by disrupting π-stacking. J Am Chem Soc 2012 0.86
54 Disabling TNF receptor signaling by induced conformational perturbation of tryptophan-107. Proc Natl Acad Sci U S A 2005 0.86
55 Identification and characterization of allophenylnorstatine-based inhibitors of plasmepsin II, an antimalarial target. Biochemistry 2002 0.86
56 The flavodoxin from Helicobacter pylori: structural determinants of thermostability and FMN cofactor binding. Biochemistry 2007 0.86
57 The native-state ensemble of proteins provides clues for folding, misfolding and function. Trends Biochem Sci 2006 0.85
58 Improvement of both plasmepsin inhibitory activity and antimalarial activity by 2-aminoethylamino substitution. Bioorg Med Chem Lett 2010 0.85
59 Mutation of Asn28 disrupts the dimerization and enzymatic activity of SARS 3CL(pro) . Biochemistry 2010 0.85
60 Antimalarial activity enhancement in hydroxymethylcarbonyl (HMC) isostere-based dipeptidomimetics targeting malarial aspartic protease plasmepsin. Bioorg Med Chem 2008 0.84
61 HIV-1 Vif N-terminal motif is required for recruitment of Cul5 to suppress APOBEC3. Retrovirology 2014 0.83
62 Ligand binding analysis and screening by chemical denaturation shift. Anal Biochem 2013 0.82
63 Search for substrate-based inhibitors fitting the S2' space of malarial aspartic protease plasmepsin II. J Pept Sci 2004 0.82
64 Design and synthesis of new tripeptide-type SARS-CoV 3CL protease inhibitors containing an electrophilic arylketone moiety. Bioorg Med Chem 2012 0.80
65 Characterization of intramolecular interactions of HIV-1 accessory protein Nef by differential scanning calorimetry. Biophys Chem 2006 0.80
66 Conformational and structural features of HIV-1 gp120 underlying the dual receptor antagonism by cross-reactive neutralizing antibody m18. Biochemistry 2011 0.80
67 Additional interaction of allophenylnorstatine-containing tripeptidomimetics with malarial aspartic protease plasmepsin II. Bioorg Med Chem Lett 2007 0.78
68 Characterization of protein-protein interactions by isothermal titration calorimetry. Methods Mol Biol 2015 0.78
69 New developments for the design, synthesis and biological evaluation of potent SARS-CoV 3CL(pro) inhibitors. Bioorg Med Chem Lett 2009 0.78
70 The integration of genomic and structural information in the development of high affinity plasmepsin inhibitors. Int J Parasitol 2002 0.78
71 Discrimination of potent inhibitors of Toxoplasma gondii enoyl-acyl carrier protein reductase by a thermal shift assay. Biochemistry 2013 0.77
72 Non-natural peptide triazole antagonists of HIV-1 envelope gp120. ChemMedChem 2012 0.77
73 Use of the quartz crystal microbalance to monitor ligand-induced conformational rearrangements in HIV-1 envelope protein gp120. Anal Bioanal Chem 2009 0.75
74 Synthesis and biochemical evaluation of triazole/tetrazole-containing sulfonamides against thrombin and related serine proteases. Bioorg Med Chem Lett 2011 0.75
75 Design, synthesis, and biological evaluation of novel dipeptide-type SARS-CoV 3CL protease inhibitors: structure-activity relationship study. Eur J Med Chem 2013 0.75
76 Development of potent dipeptide-type SARS-CoV 3CL protease inhibitors with novel P3 scaffolds: design, synthesis, biological evaluation, and docking studies. Eur J Med Chem 2013 0.75